Get started
Author

Chloé Talarmin

Quality risk management of the chimeric antigen receptor T cell pharmaceutical circuit in one of the first qualified European centers
2020 · Chloé Talarmin, Steven Kerob, et al. · Cytotherapy · 7
PDF
Validation of metaxin-2 deficient C. elegans as a model for MandibuloAcral Dysplasia associated to mtx-2 (MADaM) syndrome
2024 · Chloé Talarmin-Gas, Georges Smolyakov, et al. · Communications Biology · 4
PDF
A retrospective study of patients treated with by oral anticancer drugs: Impact of pharmacy consultation
2022 · Emmanuelle Clou, Antonin Dubois, et al. · European Journal of Oncology Pharmacy · 2
Prevention of chemotherapy-induced nausea and vomiting in patients receiving ifosfamide: High dose chemotherapy
2017 · C. Talarmin, C. Herpin, et al. · European Journal of Cancer · 1
De la biologie au circuit pharmaceutique des médicaments « cellules CAR-T »
2019 · C. Talarmin, M. Mebarki, et al. · Revue de biologie médicale.
4CPS-121 Impact of pharmaceutical consultations for new oral oncology agents
2018 · C Talarmin, M Grajozsex, et al. · Section 4: Clinical pharmacy services
Prescriptions des préparations néonatales standardisées de nutrition parentérale en Île-de-France : évaluation des pratiques professionnelles
2016 · Chloé Talarmin, Camille Imbert, et al. · Le Pharmacien Hospitalier et Clinicien
Works count: 7
Citation count: 14
H-index: 2
I10-index:
Year
Topic
Type